Anti-IgE monoclonal antibody medication for treating asthma and allergy. Brand name Xolair.
Includes fact sheet, prescribing information, and how it's manufacturered.
MedlinePlus: Omalizumab Injection
Features information about dosage, usage, warnings, and side effects.
PubMed Central: Omalizumab: A Monoclonal Anti-IgE Antibody
Descriptions of allergic asthma and allergic rhinitis pathophysiology and reviews of the pharmacologic, pharmacokinetic, pharmacodynamic, efficacy, and safety data for omalizumab.
Information about allergic asthma, how the medication works, and sections for patients, family and friends, and medical professionals.
Xolair Pregnancy Registry
Information for patients and health care providers about an observational study of pregnant women in the US taking Xolair.
JACI: Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma
Description and analysis of cases of anaphylaxis following omalizumab administration, published in The Journal of Allergy and Clinical Immunology. (December 01, 2007)
The Johns Hopkins Gazette: Why We Sneeze and Sneeze
Article about clinical testing of the experimental anti-allergy agent Anti-IgE, in a version called rhuMAb-E25. (May 10, 1999)
Last update:April 19, 2015 at 0:25:18 UTC